Sample Page
Author:
Arch Biopartners
Posted Date:
April 30, 2026
Royal Columbian Hospital begins patient recruitment in Arch Biopartners’ Phase II trial of LSALT peptide targeting CS-AKI
Arch Biopartners
April 30, 2026
Arch Biopartners Closes Non-Brokered Private Placement
Arch Biopartners
April 2, 2026
Arch Biopartners Arranges Non-Brokered Private Placement
Arch Biopartners
March 30, 2026
Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II Cardiac Surgery-Associated AKI Trial
Arch Biopartners
March 24, 2026
Arch Biopartners Announces St. Michael’s Hospital Commences Patient Dosing in the Phase II CS-AKI Trial of LSALT Peptide
Arch Biopartners
March 20, 2026
Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease
Arch Biopartners
February 9, 2026
